| Name | Title | Contact Details |
|---|
CatalystRx is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Philadelphia, PA. To find more information about CatalystRx, please visit www.catalystrx.com
careMESH is a first-of-its-kind healthcare communications platform bringing together a national provider directory, admit/discharge notifications, secure communications, and transition of care workflows into a single service. careMESH connects the care continuum by allowing any provider working with any electronic health record to communicate and collaborate with any other, instantly. careMESH`s cloud-based services efficiently allow hospitals and health systems, health information exchanges, public health agencies, and physician groups to communicate about patients, maintain complete control over when and where information is shared, and rapidly reduce reliance on outdated tools such as fax and phone calls.
QSpex embodies the ideal to provide its capital partners best-in-class financial returns, and its customers distinguishable and meaningful value. We will deliver on these fundamentals, while delivering on a higher purpose, advancing the eco-system at-large. We will do this through an inspired vision, integrated ideals, an accountable organization and compassionate leadership.
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.
Community Health Group is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Chula Vista, CA. To find more information about Community Health Group, please visit www.chtsd.com